Patrick Dentinger is a veteran in the life sciences industry with over three decades of experience in cell-based assay development and regulatory science. As co-founder and former CEO of Absorption Systems, he helped pioneer the use of in vitro cell-based assays as alternatives to animal and human testing, contributing directly to FDA-recognized standards and the first FDA-approved allogeneic gene therapy potency assay in the U.S. Today, Patrick leads CellPort Software, a purpose-built digital platform designed for the unique challenges of Advanced Therapy Medicinal Products (ATMPs). His focus is on addressing the persistent CMC liabilities that have made ATMP submissions more vulnerable to FDA CRLs and 483 observations than traditional therapies. By combining next-generation Laboratory Information Management System (LIMS) and Manufacturing Execution System (MES) functionality into a single platform, CellPort helps organizations improve data capture, streamline QA/QC, and strengthen regulatory readiness. Patrick is a strong advocate for operational efficiency in GMP laboratories, emphasizing that digitalization is not just about compliance—it is about giving teams the clarity and speed they need to reduce errors, accelerate reviews, and ultimately deliver transformative therapies to patients faster